Preclinical
There are plenty of great scientific research stories out this week. Here’s a look at just a few of them.
In its recent third-quarter report, Cambridge, Mass.-based Intellia Therapeutics indicated it is delaying its submission of an Investigational New Drug (IND) application until 2020, from late 2019.
Researchers from Van Andel Research Institute, based in Grand Rapids, Mich., found that people who had appendicitis resulting in the removal of the organ, had a lower risk of developing Parkinson’s disease later in life.
There is increasing evidence that there is some sort of association between sleep problems and dementias such as Alzheimer’s disease. This was further linked with a recent research study published in the journal Sleep.
-- Intratumoral treatment with ilixadencel, an off-the-shelf cell-based immune primer, provides synergistic anti-tumor effect and enhances efficacy of anti-PD-1 and anti-CD137 treatment in animal model --
Yesterday, researchers at the Massachusetts Institute of Technology (MIT) published research in the journal Science Advances describing yet another CRISPR improvement.
Polyphor announced today that new survival data from clinical and preclinical trials of balixafortide will be presented at the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany, October 19-23.
There are plenty of great scientific research stories out this week. Here’s a look at just a few of them.
French company Innate Pharma and UK-based AstraZeneca have had a research collaboration deal in place since 2015. The two companies announced a new multi-term deal to build on that collaboration.
There are plenty of great scientific research stories out this week. Here’s a look at just a few of them.
PRESS RELEASES